Hamish Wright, Ph.D.

Bio:

Hamish Wright, senior vice president of translational science & therapeutics business development, joined Schrödinger in 2019. He serves as a key member of the therapeutics business development team to drive partnerships and collaborations with both industry peers and academia. As part of his role, Hamish has built a team of translational researchers with expertise in drug metabolism & pharmacokinetics, clinical biomarkers and bioanalysis. Hamish came to Schrödinger after nearly 20 years at Merck Research Laboratories in roles of increasing responsibility. Most recently at Merck, Hamish served as executive director, business development and licensing. He was responsible for scientific diligence of licensing opportunities and was a member of the deal team for a number of Merck’s key oncology and immuno-oncology transactions. In previous clinical development and emerging markets roles at Merck, Hamish led numerous early clinical programs and was the product development team leader for Vaniprevir (VANIHEP™), a novel NS3/4A HCV protease inhibitor, which was approved in 2014 and commercialized in Japan. Hamish’s work in the Clinical Pharmacology unit at Merck for over a decade extended to other therapeutic areas, indications and marketed products, including those which serve patients with diabetes, respiratory disease and HIV. Hamish received his Ph.D. in pharmacology and therapeutics from McGill University and holds an academic appointment as adjunct associate professor in the Department of Pharmacology, Physiology and Neuroscience at New Jersey Medical School, now Rutgers University.